Bexel (South Korea)

The IceCube Neutrino Observatory has demonstrated the existence of an astrophysical high- energy neutrino flux with a significance exceeding 7$\sigma$. Nevertheless, the observed astrophysical neutrino flux shows no clear association with any known source class so far. The most recent searches for point sources using seven years of data from IceCube have found no significant clustering of neutrino events nor correlation with preselected sources. However not all potential neutrino sources would appear point-like, and it is therefore important to widen the search to different source topologies. The high-energy gamma-ray and cosmic-ray skies show clear indications of extended structures. In the case of cosmic-ray interactions in these environments, both gamma-ray and neutrino emission are expected, and the detection of this neutrino flux would represent unambiguous proof of the hadronic nature of the sources. In addition, an extended source search could improve sensitivity to several point sources located close together in space, for example the Cygnus region, even if the individual fluxes are too low to be detected separately. Here we present the results of an extended source analysis with seven years of IceCube data. Because the extensions of potential sources are not always known $\textit{a priori}$, five different extensions have been considered, from 1$^{\circ}$ to 5$^{\circ}$. All the five maps are consistent with the background-only hypothesis.

BLX-1060 is a water-soluble, amino acid conjugated small molecule with potent anti-inflammatory properties. Here we present the studies undertaken on its oral in vivo efficacy in LPS-induced sepsis and collagen-induced arthritis (CIA) in mice. The LPS-induced sepsis study was undertaken in male Swiss Webster mice (Simonsen), by administering with BLX-1060, followed one hour later with LPS challenge. Terminal blood was collected after 1.5 Hours of LPS and serum analyzed for inflammatory cytokines. BLX-1060 at 25, 50 and 100 mg/kg, PO, inhibited LPS induced TNF-a (20–69%) production in a dose-dependent manner. The CIA study was undertaken in male DBA/1LacJ mice (Jackson) by immunization with Bovine Type II collagen emulsified with Mycobacterium tuberculosis in Incomplete Freund's Adjuvant. The clinical symptoms of arthritic were observed from day 28 following immunization. BLX-1060 at 25, 50 and 100 mg/kg/day, PO, significantly reduced clinical symptoms of arthritis, number of afflicted paws, and paw volume thickness. Histo-pathological evaluation of the hind paws also showed significant changes in the 100 mg/kg vs the vehicle group. It is concluded that BLX-1060 is a new orally acting TNF-α inhibitor with potent anti-arthritic properties.